Mercks

LONDON — Merck & Co. Inc.’s COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a…

Stefanie Joho, 27, stands for a portrait at the home of a friend in Penn Valley, PA on Tuesday, May 9, 2017. Joho, who was diagnosed with colon cancer at 22 years old, has been in remission…

© Reuters. FILE PHOTO: A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky (Reuters) -Merck & Co said on Monday the U.S. Food and Drug…

The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir. A Japanese health ministry…

The US Food and Drug Administration has authorized Merck's second anti-viral drug Molnupiravir, revealed sources. The report said that the prescription pill, which can be taken at home, is…

Dr. Dean Li, a Merck executive, said on Thursday that preliminary laboratory studies suggested that the drug was equally effective against Omicron as it was against earlier versions of the…

The Food and Drug Administration on Thursday authorized a second antiviral pill for Covid but said it should not be a preferred treatment.The F.D.A. cleared the pill, developed by Merck and…

U.S. regulators cleared use of a Covid-19 pill from Merck MRK -0.32% & Co. and partner Ridgeback Biotherapeutics LP, the latest…

Data from the pivotal trial for the COVID-19 antiviral pill molnupiravir detailed the waning…

A new Covid-19 pill from Merck has raised hopes that it could transform the landscape of treatment options for Americans at high risk of severe disease at a time when the Omicron variant of…